@conference{9797cfa803ad4b37aa505cbc6ad1395e,
title = "Health-related quality of life (HRQL) in patients with advanced cutaneous squamous cell carcinoma (CSCC) treated with cemiplimab: Post hoc exploratory analyses of a phase II clinical trial.",
author = "Migden, \{Michael Robert\} and Danny Rischin and Medha Sasane and Vera Mastey and Anna Pavlick and Schmults, \{Chrysalyne D.\} and Zhen Chen and Guminski, \{Alexander David\} and Axel Hauschild and Denise Bury and Chang, \{Anne Lynn S.\} and Guilherme Rabinowits and Ibrahim, \{Sherrif F.\} and Israel Lowy and Fury, \{Matthew G.\} and Siyu Li and Chieh-I Chen",
note = "10033 Background: Cemiplimab-rwlc (cemiplimab), a PD-1 Inhibitor, showed a robust clinical response in patients (pts) with metastatic (mCSCC) or locally advanced (laCSCC) CSCC not eligible for curative surgery/radiation. This post hoc exploratory analysis examined data from the EORTC cancer specific 30-item HRQL questionnaire (QLQ-C30) for pts participating in a cemiplimab phase 2 clinical trial (clinicaltrials.gov NCT02760498).; Journal of Clinical Oncology ; Conference date: 20-05-2020",
year = "2020",
month = may,
day = "20",
doi = "10.1200/JCO.2020.38.15\_SUPPL.10033",
language = "American English",
}